Figure 3 | Scientific Reports

Figure 3

From: Sustained Elevation of Intraocular Pressure Associated with Intravitreal Administration of Anti-vascular Endothelial Growth Factor: A Systematic Review and Meta-Analysis

Figure 3

Forest plot showing the association of intravitreal anti-VEGF mono-therapy with risk of sustained elevation of IOP (SE-IOP) in various subgroups with a fixed-effects model.

(a) Different agents: RRs for ranibizumab and aflibercept; (b) Different follow-up periods: RRs at 6, 12, and 23 months; (c) Different diseases: RRs for diabetic macular edema (DME) and central retinal vein occlusion (CRVO); (d) Exclusion of pre-existing glaucoma: RRs for exclusion and non-exclusion of pre-existing glaucoma patients. M-H, Mantel Haenszel statistics; RR, risk ratio; CI, confidence interval.

Back to article page